NO313997B1 - Nye N-substituerte sykliske aminer, fremgangsmåte ved fremstilling derav ogfarmasöytiske sammensetninger inneholdende slike - Google Patents
Nye N-substituerte sykliske aminer, fremgangsmåte ved fremstilling derav ogfarmasöytiske sammensetninger inneholdende slikeInfo
- Publication number
- NO313997B1 NO313997B1 NO19974253A NO974253A NO313997B1 NO 313997 B1 NO313997 B1 NO 313997B1 NO 19974253 A NO19974253 A NO 19974253A NO 974253 A NO974253 A NO 974253A NO 313997 B1 NO313997 B1 NO 313997B1
- Authority
- NO
- Norway
- Prior art keywords
- methoxybenzyl
- piperidine
- ylcarbonyl
- cyclopentyloxy
- substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 3
- -1 monocyclic hydrocarbon Chemical class 0.000 claims abstract description 10
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- ZCBSYDRSUGBQGL-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-methylimidazol-4-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN(C)C=N1 ZCBSYDRSUGBQGL-UHFFFAOYSA-N 0.000 claims description 2
- CGAYZDAKNJYZIW-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-pyridin-3-ylmethanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CN=C1 CGAYZDAKNJYZIW-UHFFFAOYSA-N 0.000 claims description 2
- SWOSLDCNMRHYTB-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-quinolin-4-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=CC=CC=C3N=CC=2)C=C1OC1CCCC1 SWOSLDCNMRHYTB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- UEFKRXPATUYVAW-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-quinoxalin-2-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2N=C3C=CC=CC3=NC=2)C=C1OC1CCCC1 UEFKRXPATUYVAW-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- JLWHQVAJVQMMBT-UHFFFAOYSA-N 4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC1CCNCC1 JLWHQVAJVQMMBT-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- XQCZCHSJBPNFHE-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1h-imidazol-5-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CNC=N1 XQCZCHSJBPNFHE-UHFFFAOYSA-N 0.000 description 2
- UUBYHCLHAVPMRF-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(CC=2C=C(OC3CCCC3)C(OC)=CC=2)CC1 UUBYHCLHAVPMRF-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000003935 benzaldehydes Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HUEUQPHVKNEACH-UHFFFAOYSA-N (2-chloro-6-methoxypyridin-4-yl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound ClC1=NC(OC)=CC(C(=O)N2CCC(CC=3C=C(OC4CCCC4)C(OC)=CC=3)CC2)=C1 HUEUQPHVKNEACH-UHFFFAOYSA-N 0.000 description 1
- DWDDKTDAKADIAY-UHFFFAOYSA-N (2-chloro-6-methylpyridin-4-yl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC(C)=NC(Cl)=C1 DWDDKTDAKADIAY-UHFFFAOYSA-N 0.000 description 1
- IWGVWWCFABTJFI-UHFFFAOYSA-N (2-chloropyridin-4-yl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=NC(Cl)=C1 IWGVWWCFABTJFI-UHFFFAOYSA-N 0.000 description 1
- HYQJZMCVRWIZSC-UHFFFAOYSA-N (4-chlorophenyl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(Cl)C=C1 HYQJZMCVRWIZSC-UHFFFAOYSA-N 0.000 description 1
- OEQDFYHHFDBZIC-UHFFFAOYSA-N (5-chloropyrazin-2-yl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN=C(Cl)C=N1 OEQDFYHHFDBZIC-UHFFFAOYSA-N 0.000 description 1
- USBCBADNRVBDAC-UHFFFAOYSA-N (6-chloropyridazin-3-yl)-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(Cl)N=N1 USBCBADNRVBDAC-UHFFFAOYSA-N 0.000 description 1
- AYJLVIJCRIIGNK-UHFFFAOYSA-N 1,3-benzoxazol-5-yl-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C=C3N=COC3=CC=2)C=C1OC1CCCC1 AYJLVIJCRIIGNK-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- MUGHSKVFNQYDER-UHFFFAOYSA-N 1h-imidazol-5-yl-[4-[(4-methoxy-3-pentoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC)C(OCCCCC)=CC(CC2CCN(CC2)C(=O)C=2N=CNC=2)=C1 MUGHSKVFNQYDER-UHFFFAOYSA-N 0.000 description 1
- HKKXQTMYHHFMPZ-UHFFFAOYSA-N 1h-imidazol-5-yl-[4-[(4-methoxy-3-propan-2-yloxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1CC1CCN(C(=O)C=2N=CNC=2)CC1 HKKXQTMYHHFMPZ-UHFFFAOYSA-N 0.000 description 1
- KGCJNWWHOBGECP-UHFFFAOYSA-N 1h-imidazol-5-yl-[4-[[4-methoxy-3-(2-methyl-5-phenylpentyl)phenyl]methyl]piperidin-1-yl]methanone Chemical compound C1=C(CC(C)CCCC=2C=CC=CC=2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN=CN1 KGCJNWWHOBGECP-UHFFFAOYSA-N 0.000 description 1
- IFUDGEQYWRWUQE-UHFFFAOYSA-N 3h-benzimidazol-5-yl-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C=C3NC=NC3=CC=2)C=C1OC1CCCC1 IFUDGEQYWRWUQE-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- MKUPYFRLKNJKGY-UHFFFAOYSA-N 4-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]benzoic acid Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(C(O)=O)C=C1 MKUPYFRLKNJKGY-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- HSAHIPCORHXRIG-UHFFFAOYSA-N 5-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]-1h-pyrimidine-2,4-dione Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CNC(=O)NC1=O HSAHIPCORHXRIG-UHFFFAOYSA-N 0.000 description 1
- YHMYWCUVEIKEHC-UHFFFAOYSA-N 6-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]-1h-pyrimidine-2,4-dione Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC(=O)NC(=O)N1 YHMYWCUVEIKEHC-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- SSXSJHIDFAGGDV-UHFFFAOYSA-N [2-chloro-4-(trifluoromethyl)pyridin-3-yl]-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=C(Cl)N=CC=C1C(F)(F)F SSXSJHIDFAGGDV-UHFFFAOYSA-N 0.000 description 1
- SWYYNZNFVGQQEB-UHFFFAOYSA-N [4-[(3-butoxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-methylimidazol-4-yl)methanone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2CCN(CC2)C(=O)C=2N=CN(C)C=2)=C1 SWYYNZNFVGQQEB-UHFFFAOYSA-N 0.000 description 1
- YONBGWYITIULOY-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1,2,5-trimethylpyrrol-3-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=C(C)N(C)C=1C YONBGWYITIULOY-UHFFFAOYSA-N 0.000 description 1
- SVBIRTYFOBSPJM-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-methylindol-3-yl)methanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=CC=CC=C3N(C)C=2)C=C1OC1CCCC1 SVBIRTYFOBSPJM-UHFFFAOYSA-N 0.000 description 1
- IBPHWHFNMHAXRL-UHFFFAOYSA-M [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-methylpyridin-1-ium-3-yl)methanone iodide Chemical compound [I-].C1(CCCC1)OC=1C=C(CC2CCN(CC2)C(=O)C=2C=[N+](C=CC=2)C)C=CC=1OC IBPHWHFNMHAXRL-UHFFFAOYSA-M 0.000 description 1
- MCESQTPOYPJDLZ-UHFFFAOYSA-M [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-methylpyridin-1-ium-4-yl)methanone iodide Chemical compound [I-].C1(CCCC1)OC=1C=C(CC2CCN(CC2)C(=O)C2=CC=[N+](C=C2)C)C=CC1OC MCESQTPOYPJDLZ-UHFFFAOYSA-M 0.000 description 1
- ZKTOVCDIWIQXKL-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1-propan-2-ylimidazol-4-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN(C(C)C)C=N1 ZKTOVCDIWIQXKL-UHFFFAOYSA-N 0.000 description 1
- YHGKAMGNDRBCEP-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1h-indol-3-yl)methanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=CC=CC=C3NC=2)C=C1OC1CCCC1 YHGKAMGNDRBCEP-UHFFFAOYSA-N 0.000 description 1
- FAQZCGSOAYRSCX-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(1h-pyrazol-4-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=NNC=1 FAQZCGSOAYRSCX-UHFFFAOYSA-N 0.000 description 1
- ZAZUCRPBJCSOBP-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(2,5-dimethyl-1h-pyrrol-3-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=C(C)NC=1C ZAZUCRPBJCSOBP-UHFFFAOYSA-N 0.000 description 1
- CLJKPGJSEMQTOF-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(2,6-dichlorophenyl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=C(Cl)C=CC=C1Cl CLJKPGJSEMQTOF-UHFFFAOYSA-N 0.000 description 1
- CJBOGZXQUYMXPP-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(3,4-dimethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCC(CC=2C=C(OC3CCCC3)C(OC)=CC=2)CC1 CJBOGZXQUYMXPP-UHFFFAOYSA-N 0.000 description 1
- DCJZZBZJGIVDGN-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(3-methylimidazol-4-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN=CN1C DCJZZBZJGIVDGN-UHFFFAOYSA-N 0.000 description 1
- AWTOLGZYPPVZMH-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(3-nitrophenyl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CC([N+]([O-])=O)=C1 AWTOLGZYPPVZMH-UHFFFAOYSA-N 0.000 description 1
- BJOLFFJAJVUTKV-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(4-nitrophenyl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C([N+]([O-])=O)C=C1 BJOLFFJAJVUTKV-UHFFFAOYSA-N 0.000 description 1
- YWBWJCXLGBWZMX-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(5-fluoro-1h-indol-2-yl)methanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2NC3=CC=C(F)C=C3C=2)C=C1OC1CCCC1 YWBWJCXLGBWZMX-UHFFFAOYSA-N 0.000 description 1
- ZELSOPJZEULDOE-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(5-methyl-1,2-oxazol-3-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=C(C)ON=1 ZELSOPJZEULDOE-UHFFFAOYSA-N 0.000 description 1
- AYWFOHWGEVHCAR-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(furan-2-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CO1 AYWFOHWGEVHCAR-UHFFFAOYSA-N 0.000 description 1
- AAUSEFXJCSYBPA-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(furan-3-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=COC=1 AAUSEFXJCSYBPA-UHFFFAOYSA-N 0.000 description 1
- QSGNAXPLTJCXGD-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-(thiadiazol-4-yl)methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CSN=N1 QSGNAXPLTJCXGD-UHFFFAOYSA-N 0.000 description 1
- JEDYXMAVIIMPSA-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-[4-(dimethylamino)phenyl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(N(C)C)C=C1 JEDYXMAVIIMPSA-UHFFFAOYSA-N 0.000 description 1
- OKTBOCVGHWIGIR-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 OKTBOCVGHWIGIR-UHFFFAOYSA-N 0.000 description 1
- GVSQYVCZBYMFFM-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-isoquinolin-3-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2N=CC3=CC=CC=C3C=2)C=C1OC1CCCC1 GVSQYVCZBYMFFM-UHFFFAOYSA-N 0.000 description 1
- BRUQNMXLQURQLM-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-isoquinolin-4-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=CC=CC=C3C=NC=2)C=C1OC1CCCC1 BRUQNMXLQURQLM-UHFFFAOYSA-N 0.000 description 1
- MXZFFNBLONEXAO-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-quinolin-3-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C=C3C=CC=CC3=NC=2)C=C1OC1CCCC1 MXZFFNBLONEXAO-UHFFFAOYSA-N 0.000 description 1
- GCKYGHGSQOSDAQ-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-quinolin-5-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=CC=CN=C3C=CC=2)C=C1OC1CCCC1 GCKYGHGSQOSDAQ-UHFFFAOYSA-N 0.000 description 1
- YTZDKSOUIJUVBI-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-quinolin-8-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2C3=NC=CC=C3C=CC=2)C=C1OC1CCCC1 YTZDKSOUIJUVBI-UHFFFAOYSA-N 0.000 description 1
- PHOHFERKHUXKJF-UHFFFAOYSA-N [4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidin-1-yl]-thiophen-2-ylmethanone Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CS1 PHOHFERKHUXKJF-UHFFFAOYSA-N 0.000 description 1
- MTSHNEWVVFPZIO-UHFFFAOYSA-N [4-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]phenyl] acetate Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CC=C(OC(C)=O)C=C1 MTSHNEWVVFPZIO-UHFFFAOYSA-N 0.000 description 1
- UEYKYCUGMBLLNL-UHFFFAOYSA-N [4-[[3-(cyclopentylmethyl)-4-methoxyphenyl]methyl]piperidin-1-yl]-(1h-pyrazol-4-yl)methanone Chemical compound C1=C(CC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C=1C=NNC=1 UEYKYCUGMBLLNL-UHFFFAOYSA-N 0.000 description 1
- AVQXXVGATZJHQZ-UHFFFAOYSA-N [4-[[3-(cyclopentylmethyl)-4-methoxyphenyl]methyl]piperidin-1-yl]-quinoxalin-2-ylmethanone Chemical compound COC1=CC=C(CC2CCN(CC2)C(=O)C=2N=C3C=CC=CC3=NC=2)C=C1CC1CCCC1 AVQXXVGATZJHQZ-UHFFFAOYSA-N 0.000 description 1
- DPJBSWJAFOSJKR-UHFFFAOYSA-N [4-[[3-cyclopentyloxy-4-(difluoromethoxy)phenyl]methyl]piperidin-1-yl]-(3-methylimidazol-4-yl)methanone Chemical compound CN1C=NC=C1C(=O)N1CCC(CC=2C=C(OC3CCCC3)C(OC(F)F)=CC=2)CC1 DPJBSWJAFOSJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- NKSNIIYOVUPEEC-UHFFFAOYSA-N methyl 4-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)N1CCC(CC=2C=C(OC3CCCC3)C(OC)=CC=2)CC1 NKSNIIYOVUPEEC-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- NDSXBLFCJPYAKP-UHFFFAOYSA-N n-[5-[4-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]piperidine-1-carbonyl]pyridin-3-yl]acetamide Chemical compound C1=C(OC2CCCC2)C(OC)=CC=C1CC(CC1)CCN1C(=O)C1=CN=CC(NC(C)=O)=C1 NDSXBLFCJPYAKP-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9611501A FR2753706B1 (fr) | 1996-09-20 | 1996-09-20 | Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant |
Publications (3)
Publication Number | Publication Date |
---|---|
NO974253D0 NO974253D0 (no) | 1997-09-15 |
NO974253L NO974253L (no) | 1998-03-23 |
NO313997B1 true NO313997B1 (no) | 2003-01-13 |
Family
ID=9495928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19974253A NO313997B1 (no) | 1996-09-20 | 1997-09-15 | Nye N-substituerte sykliske aminer, fremgangsmåte ved fremstilling derav ogfarmasöytiske sammensetninger inneholdende slike |
Country Status (18)
Country | Link |
---|---|
US (1) | US5919801A (da) |
EP (1) | EP0831090B1 (da) |
JP (1) | JPH10101645A (da) |
AT (1) | ATE191717T1 (da) |
AU (1) | AU718489B2 (da) |
BR (1) | BR9704757A (da) |
CA (1) | CA2216664C (da) |
DE (1) | DE69701662T2 (da) |
DK (1) | DK0831090T3 (da) |
ES (1) | ES2147427T3 (da) |
FR (1) | FR2753706B1 (da) |
GR (1) | GR3033509T3 (da) |
HU (1) | HU221811B1 (da) |
NO (1) | NO313997B1 (da) |
NZ (1) | NZ328789A (da) |
PL (1) | PL322192A1 (da) |
PT (1) | PT831090E (da) |
ZA (1) | ZA978462B (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
EP1080078B1 (en) * | 1998-05-22 | 2006-02-01 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
US6340685B1 (en) | 1998-05-22 | 2002-01-22 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6130235A (en) * | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6448257B1 (en) | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
BR9913152A (pt) * | 1998-08-26 | 2001-05-15 | Smithkline Beecham Corp | Terapias para tratamento de doenças pulmonares |
IL146309A (en) | 1999-05-21 | 2008-03-20 | Scios Inc | Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38 |
KR100515905B1 (ko) * | 2000-01-31 | 2005-09-21 | 주식회사 엘지생명과학 | 피롤아미드의 새로운 제조방법 |
US20030207845A1 (en) * | 2001-02-08 | 2003-11-06 | Keating Elizabeth T. | Method and compositions for treating an inflammatory disease |
BR0108087A (pt) * | 2000-02-08 | 2002-10-29 | Smithkline Beecham Corp | Método e composições para o tratamento de uma doença inflamatória |
DE10035927A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
DE10035928A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
ES2325353T3 (es) * | 2000-08-11 | 2009-09-02 | Ono Pharmaceutical Co., Ltd. | Derivados de piperidina y medicamentos a base de tales ingredientes activos. |
US20040219552A1 (en) * | 2001-08-14 | 2004-11-04 | Ali Ait Ikhlef | Novel molecular target for neurotoxicity |
FR2856595B1 (fr) * | 2003-06-27 | 2008-05-30 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de deficits cognitifs. |
JP2011504505A (ja) | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールpde4抑制剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6850M (da) * | 1967-12-05 | 1969-04-08 | ||
US5459151A (en) * | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
US5530012A (en) * | 1994-12-22 | 1996-06-25 | Bristol-Myers Squibb Co. | 3-alkoxybenzylpiperidine derivatives as melatonergic agents |
US5703239A (en) * | 1995-06-02 | 1997-12-30 | Bristol-Myers Squibb Company | Indanylpiperidines as melatonergic agents |
-
1996
- 1996-09-20 FR FR9611501A patent/FR2753706B1/fr not_active Expired - Fee Related
-
1997
- 1997-09-12 JP JP9248357A patent/JPH10101645A/ja active Pending
- 1997-09-15 NO NO19974253A patent/NO313997B1/no unknown
- 1997-09-19 DE DE69701662T patent/DE69701662T2/de not_active Expired - Fee Related
- 1997-09-19 PL PL97322192A patent/PL322192A1/xx unknown
- 1997-09-19 AT AT97402175T patent/ATE191717T1/de not_active IP Right Cessation
- 1997-09-19 US US08/934,409 patent/US5919801A/en not_active Expired - Fee Related
- 1997-09-19 ZA ZA9708462A patent/ZA978462B/xx unknown
- 1997-09-19 DK DK97402175T patent/DK0831090T3/da active
- 1997-09-19 AU AU38362/97A patent/AU718489B2/en not_active Ceased
- 1997-09-19 PT PT97402175T patent/PT831090E/pt unknown
- 1997-09-19 ES ES97402175T patent/ES2147427T3/es not_active Expired - Lifetime
- 1997-09-19 EP EP97402175A patent/EP0831090B1/fr not_active Expired - Lifetime
- 1997-09-19 CA CA002216664A patent/CA2216664C/fr not_active Expired - Fee Related
- 1997-09-19 BR BR9704757A patent/BR9704757A/pt unknown
- 1997-09-19 HU HU9701561A patent/HU221811B1/hu not_active IP Right Cessation
- 1997-09-19 NZ NZ328789A patent/NZ328789A/en unknown
-
2000
- 2000-05-25 GR GR20000401200T patent/GR3033509T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69701662D1 (de) | 2000-05-18 |
DE69701662T2 (de) | 2000-11-23 |
HU221811B1 (hu) | 2003-01-28 |
BR9704757A (pt) | 1998-09-01 |
ES2147427T3 (es) | 2000-09-01 |
AU3836297A (en) | 1998-03-26 |
GR3033509T3 (en) | 2000-09-29 |
NO974253L (no) | 1998-03-23 |
HUP9701561A3 (en) | 1998-07-28 |
CA2216664A1 (fr) | 1998-03-20 |
JPH10101645A (ja) | 1998-04-21 |
NO974253D0 (no) | 1997-09-15 |
FR2753706B1 (fr) | 1998-10-30 |
CA2216664C (fr) | 2002-05-21 |
ATE191717T1 (de) | 2000-04-15 |
HUP9701561A2 (hu) | 1998-05-28 |
AU718489B2 (en) | 2000-04-13 |
US5919801A (en) | 1999-07-06 |
DK0831090T3 (da) | 2000-09-11 |
PL322192A1 (en) | 1998-03-30 |
NZ328789A (en) | 1998-02-26 |
EP0831090A1 (fr) | 1998-03-25 |
EP0831090B1 (fr) | 2000-04-12 |
HU9701561D0 (en) | 1997-11-28 |
FR2753706A1 (fr) | 1998-03-27 |
ZA978462B (en) | 1998-03-24 |
PT831090E (pt) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO313997B1 (no) | Nye N-substituerte sykliske aminer, fremgangsmåte ved fremstilling derav ogfarmasöytiske sammensetninger inneholdende slike | |
RU2351596C2 (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида и их применение в терапии | |
KR100605140B1 (ko) | 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법 | |
RU2270833C2 (ru) | Гетероциклическое соединение | |
US20030073699A1 (en) | Compounds and methods to treat cardiac failure and other disorders | |
US4680296A (en) | Piperidine derivatives and pharmaceutical compositions containing them | |
CA2181376A1 (en) | Aralkylamino substituted azacyclic therapeutic agents | |
JPH11513382A (ja) | 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 | |
JP2008133297A (ja) | ムスカリン性アゴニスト | |
CN102317278B (zh) | Ccr2的4-氮杂环丁烷基-1-杂芳基-环己醇拮抗剂 | |
NO318451B1 (no) | 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmater for fremstilling av disse, medisinske preparater inneholdende disse, og mellomprodukter for disse forbindelser | |
CN103998429B (zh) | 作为ccr(4)拮抗剂的取代的苯胺类 | |
NO180632B (no) | 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler | |
WO2005060959A1 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
WO1994021627A1 (en) | Indole derivatives as dopamine d4 antagonists | |
DK168291B1 (da) | N-substituerede diphenylpiperidiner, fremgangsmåde til fremstilling deraf, lægemiddel indeholdende forbindelserne samt anvendelse af forbindelserne samt anvendelse af forbindelserne til fremstilling af et lægemiddel til anvendelse til forebyggelse eller behandling af fedme | |
US20060293297A1 (en) | Cyanofluoropyrrolidine derviative | |
WO1998049144A1 (fr) | Nouveau derive de dihydropyridine | |
EP2516416A1 (en) | Crth2 modulators | |
IL146309A (en) | Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38 | |
JP3916092B2 (ja) | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 | |
JP2006506346A (ja) | p38キナーゼ阻害剤としてのインドール系誘導体 | |
WO2020079606A9 (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators | |
AU2006268527B2 (en) | Novel 1H-indole-pyridinecarboxamide and 1H-indole-piperidinecarboxamide derivatives and their use as hydroxylase tyrosine inducers | |
EP1789389A1 (en) | Piperidine compound and process for preparing the same |